Get the Stockscreener App
1.43
2.14%
0.03
Mira Pharmaceuticals Inc stock is traded at $1.43, with a volume of 170.98K.
It is up +2.14% in the last 24 hours and down -18.29% over the past month.
Mira Pharmaceuticals Inc is a pre-clinical-stage pharmaceutical development company with two neuroscience programs targeting a broad range of neurologic and neuropsychiatric disorders. The company's novel oral pharmaceutical marijuana, MIRA-55, is under investigation for treating adult patients suffering from anxiety and cognitive decline, often associated with early-stage dementia.
See More
Previous Close:
$1.40
Open:
$1.4
24h Volume:
170.98K
Relative Volume:
0.14
Market Cap:
$27.27M
Revenue:
-
Net Income/Loss:
$-11.24M
P/E Ratio:
-1.8779
EPS:
-0.7615
Net Cash Flow:
$-4.79M
1W Performance:
-4.67%
1M Performance:
-18.29%
6M Performance:
+30.00%
1Y Performance:
-23.53%
1-Day Range:
$1.39
$1.4554
1-Week Range:
$1.3601
$1.5355
52-Week Range:
$0.73
$2.70
Mira Pharmaceuticals Inc Stock (MIRA) Company Profile
Name
Mira Pharmaceuticals Inc
Sector
Industry
Phone
813-369-5150
Address
1200 BRICKELL AVENUE, MIAMI
Compare MIRA with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
MIRA
Mira Pharmaceuticals Inc
|
1.43 | 27.34M | 0 | -11.24M | -4.79M | -0.7615 |
|
LLY
Lilly Eli Co
|
711.68 | 625.77B | 53.26B | 13.80B | -50.20M | 15.30 |
|
JNJ
Johnson Johnson
|
179.29 | 424.47B | 90.62B | 22.66B | 18.18B | 9.35 |
|
ABBV
Abbvie Inc
|
210.60 | 364.92B | 58.33B | 3.73B | 18.24B | 2.10 |
|
NVS
Novartis Ag Adr
|
126.98 | 240.07B | 53.40B | 13.68B | 16.89B | 6.9231 |
|
MRK
Merck Co Inc
|
87.37 | 210.36B | 63.43B | 16.42B | 14.72B | 6.49 |
Mira Pharmaceuticals Inc Stock (MIRA) Latest News
Technical Charts Suggest Momentum Shift in MIRA Pharmaceuticals Inc.Earnings Performance Report & Verified Momentum Stock Watchlist - beatles.ru
MIRA Pharmaceuticals Announces Completion of Phase 1 Single Ascending Dose for Oral Ketamir-2 with No Safety Concerns, Advances to Multiple Ascending Dose Stage - The Florida Times-Union
Sentiment analysis tools applied to MIRA Pharmaceuticals Inc.July 2025 Pullbacks & Weekly Chart Analysis and Guides - Newser
MIRA Pharmaceuticals Inc. stock prediction for this weekWeekly Gains Summary & High Conviction Buy Zone Picks - Newser
Is this a good reentry point in MIRA Pharmaceuticals Inc.Market Sentiment Review & Free High Return Stock Watch Alerts - Newser
Price action breakdown for MIRA Pharmaceuticals Inc.Weekly Stock Report & High Return Trade Guides - Newser
What makes MIRA Pharmaceuticals Inc. stock price move sharplyQuarterly Profit Summary & Smart Allocation Stock Reports - Newser
What’s the recovery path for long term holders of MIRA Pharmaceuticals Inc.Market Volume Summary & AI Enhanced Trading Alerts - Newser
Applying sector rotation models to MIRA Pharmaceuticals Inc.Earnings Overview Report & Real-Time Buy Zone Alerts - Newser
Applying Elliott Wave Theory to MIRA Pharmaceuticals Inc.Buy Signal & Low Risk High Reward Ideas - Newser
Will breakout in MIRA Pharmaceuticals Inc. lead to full recoveryJuly 2025 EndofMonth & Risk Controlled Daily Trade Plans - Newser
What recovery options are there for MIRA Pharmaceuticals Inc.Weekly Investment Summary & Stock Timing and Entry Methods - Newser
Sector ETF performance correlation with MIRA Pharmaceuticals Inc.Breakout Watch & Low Drawdown Momentum Ideas - Newser
Comparing MIRA Pharmaceuticals Inc. in custom built stock radars2025 Price Action Summary & Weekly Consistent Profit Watchlists - Newser
Volume spikes in MIRA Pharmaceuticals Inc. stock – what they meanExit Point & AI Enhanced Trading Alerts - Newser
MIRA Pharmaceuticals Completes Phase 1 Trial for Ketamir-2 - TipRanks
MIRA Pharmaceuticals completes phase 1 SAD trial for pain drug - Investing.com
Today's SEC FilingsLatest 10-K, 10-Q, 8-K Forms - Stock Titan
Zero Safety Concerns: MIRA's Novel Oral Pain Drug Ketamir-2 Aces First Human Trial, Targets 51M Patient Market - Stock Titan
Mira Pharmaceuticals completes Phase 1 single dose trial for Ketamir-2 with no safety concerns - Investing.com
How to build a custom watchlist for MIRA Pharmaceuticals Inc.July 2025 Weekly Recap & High Accuracy Investment Signals - Newser
Understanding MIRA Pharmaceuticals Inc.’s price movementJuly 2025 Levels & Real-Time Stock Movement Alerts - Newser
How hedge fund analytics apply to MIRA Pharmaceuticals Inc. stockEarnings Performance Report & Stepwise Entry and Exit Trade Signals - Newser
What to expect from MIRA Pharmaceuticals Inc. in the next 30 daysPortfolio Value Report & Growth Focused Entry Reports - Newser
How MIRA Pharmaceuticals Inc. stock performs during market volatilityEarnings Recap Summary & Daily Profit Maximizing Trade Tips - Newser
Combining price and volume data for MIRA Pharmaceuticals Inc.Weekly Risk Report & Weekly Top Gainers Trade List - Newser
MIRA Pharmaceuticals Inc. stock trendline breakdownLong Setup & Daily Volume Surge Trade Alerts - Newser
Analyzing drawdowns of MIRA Pharmaceuticals Inc. with statistical toolsQuarterly Portfolio Summary & Trade Opportunity Analysis - Newser
Visual trend scoring systems applied to MIRA Pharmaceuticals Inc.2025 Big Picture & Breakout Confirmation Trade Signals - Newser
Can MIRA Pharmaceuticals Inc. rally from current levels2025 Short Interest & Reliable Momentum Entry Alerts - Newser
Identifying reversal signals in MIRA Pharmaceuticals Inc.July 2025 Retail & Reliable Price Breakout Alerts - Newser
Is MIRA Pharmaceuticals Inc. exposed to currency risksJuly 2025 Reactions & Weekly Stock Performance Updates - newsyoung.net
Mira Pharmaceuticals Inc reports results for the quarter ended June 30Earnings Summary - TradingView
How moving averages guide MIRA Pharmaceuticals Inc. tradingShare Buyback & Real-Time Volume Spike Alerts - Newser
Is it too late to sell MIRA Pharmaceuticals Inc.2025 AllTime Highs & Smart Allocation Stock Tips - Newser
Forecasting MIRA Pharmaceuticals Inc. price range with options dataJuly 2025 Momentum & Risk Adjusted Swing Trade Ideas - Newser
MIRA Pharmaceuticals’ Second Ketamir-2 Manuscript Accepted for Peer-Reviewed Publication Demonstrating Superior Efficacy in Preclinical Neuropathic Pain Models Versus Ketamine, Gabapentin, or Pregabalin - The News-Press
Published on: 2025-08-13 06:59:24 - Newser
Published on: 2025-08-13 05:51:00 - Newser
Mira Pharmaceuticals Inc Stock (MIRA) Financials Data
Revenue
Net Income
Cash Flow
EPS
Mira Pharmaceuticals Inc Stock (MIRA) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Aminov Erez | Chief Executive Officer |
Nov 20 '24 |
Sale |
1.27 |
44,590 |
56,629 |
1,061,200 |
1.46%
1.18%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):